There is a potential advantage of performing surgery at the primary tumor and/or metastatic lesions in different advanced urologic tumors (prostate, kidney, bladder, penis). This advantage might be to achieve curation within the framework of multimodality therapy (together with radiotherapy and/or systemic therapy) or to improve the disease-free survival and quality of life due to a cytoreductive effect. Most of the evidence is derived from retrospective data. Conventional diagnostic tools (imaging, pathology) are currently insufficient to determinate who will have a clear benefit from surgery in this setting. Biomarkers in blood and urine appear to be promising in appropriate patient selection. The aim of this study is to prospectively evaluate patients with advanced urologic malignancies who underwent surgery and to collect a biobank of blood and urine for future biomarker development.